In The News
June 2, 2026
NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies
FRANKLIN, OHIO & BRONX, NEW YORK — June 2026 — NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix retains rights to therapeutic applications of the antibody panel.
Quantifying Protein State Transitions
The licensed antibody portfolio represents a significant advancement in the characterization of Alzheimer’s disease and other Tau-related pathologies. These highly specialized reagents enable differentiation among distinct Tau species, including cleavage-specific and conformationally altered forms located within the protein filament core.
This degree of specificity provides a foundation for distinguishing Alzheimer’s disease-associated Tau pathology from related neurodegenerative disorders, including Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), while also enabling quantitative characterization of disease-associated protein aggregation.
NanoDetection has integrated these antibodies into its proprietary TRACE-Tau™ platform, establishing a quantitative framework for monitoring protein-state transitions across the Alzheimer’s disease pathological continuum. The resulting assays are being developed for deployment on NanoDetection’s proprietary Luminorix™ instrument system using the company’s Accuglo™ chemiluminescent assay architecture.
Human Sample Characterization and Translational Validation
Data generated from analyses of multiple Alzheimer’s disease patient samples have demonstrated detection and characterization of aggregated Tau species across a variety of human sample types, supporting the translational relevance of the antibody platform.
Validation of the technology in cerebrospinal fluid remains promising as NanoDetection, in collaboration with the UMass Chan Medical School Morphology and SCOPE cores, continues to advance clinical verification of the diagnostic platform.
Unlike conventional assays that primarily quantify total or phosphorylated Tau, the NanoDetection platform is designed to specifically interrogate aggregated Tau species believed to be more closely associated with active disease pathology.
Leadership Commentary
“This agreement represents a major strategic milestone for NDT,” said Douglas Durand, Chief Executive Officer of NanoDetection Technology. “The Oligomerix antibody portfolio provides NDT with a powerful scientific and commercial foundation for the development of next-generation protein characterization and neurodegenerative diagnostic platforms.”
James Moe, Chief Executive Officer of Oligomerix, added: “We are pleased to partner with NDT as they advance diagnostic applications utilizing the Oligomerix Tau antibody portfolio. We believe these antibodies may provide important tools for characterizing aggregated and conformational Tau species associated with neurodegenerative disease and related conditions, while further expanding Oligomerix’s platform of Tau-focused technologies.”
About NanoDetection Technology, Incorporated
Located in Franklin, Ohio, NanoDetection Technology develops advanced diagnostic platforms for complex diseases, including neurodegeneration, oncology, and infectious disease. Its Luminorix™ instrument system is designed to translate high-precision assay technologies into rapid clinical applications.
About Oligomerix, Incorporated
Headquartered in the Bronx, New York, Oligomerix is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule inhibitors of protein self-association for Alzheimer’s disease and rare neurodegenerative disorders, including Progressive Supranuclear Palsy and Frontotemporal Dementia. Oligomerix’s lead compound, OLX-07010, has completed Phase 1a and is preparing to enter clinical trials in Alzheimer’s disease patients.
February 17th, 2026
Luminorix™ has been selected as the brand for our chemiluminescent diagnostic instrument, designed for high-sensitivity, laboratory-grade and confirmatory testing. The name reflects precision, sensitivity, and scientific rigor, while providing a scalable foundation for future instrument configurations.
AccuGlo™ has been selected as the brand for our digital intelligence platform and field-deployable assay family. The name conveys accuracy and clarity, reflecting AccuGlo’s role in delivering rapid screening in the field and transforming results—whether generated in the field or on Luminorix—into actionable insight through analytics, reporting, and surveillance.
Together, Luminorix™ powered by the AccuGlo™ platform presents a unified diagnostics ecosystem—from field screening and confirmatory testing to insight and decision-making.
October 16th, 2025
NanoDetection Technology™ Named Top Biochip IP Technology.
We’re thrilled to be recognized by Semiconductor Review as the Top BioChip IP Technology of the Year, following industry nominations and a rigorous expert review. This achievement highlights our relentless drive to innovate and lead the next generation of biotechnology. We would also like to thank Lateral Dx and Richard Campbell for their continued support over the years.
August 8th, 2025
Welcome, Edward Smith
We’re proud to welcome Ed Smith, RPh, MBA, BCMAS, to the Board of Directors at NanoDetection Technology™!
Ed is a seasoned healthcare and life sciences executive with deep expertise across diagnostics, pharmaceuticals, and health systems. He brings a rare blend of clinical insight and strategic leadership—spanning commercialization, market development, interdisciplinary operations, and strategic alliances—that will be instrumental as we advance our proprietary chemiluminescence-based platform for infectious disease detection in human and veterinary health.
We’re thrilled to have Ed on board and look forward to the impact of his contributions.